open access

Vol 14, No 3 (2019)
Heart failure
Published online: 2019-07-04
Get Citation

Peripartum cardiomyopathy: still unknown. The current state of knowledge

Kiet Anh Nguyen, Kamila Gniady, Małgorzata Lelonek
Folia Cardiologica 2019;14(3):315-323.

open access

Vol 14, No 3 (2019)
Heart failure
Published online: 2019-07-04

Abstract

Peripartum cardiomyopathy (PPCM) is defined as idiopathic cardiomyopathy which occurs at the end of pregnancy or in the first few months after delivery, with symptoms of heart failure (HF) secondary to left ventricular dysfunction, and at the same time no other cause for this condition. The pathomechanism of the disease has not yet been fully understood, but it is probably based on the interaction of complex factors. The clinical course of PPCM varies from life-threatening acute heart failure to mild symptoms mimicking the symptoms typical of the perinatal period. In Europe, PPCM is a rare disease but there are areas of the world where it occurs in one in every 300 cases. The treatment of PPCM is similar to that of HF with reduced ejection fraction. However, it is important to exclude drugs with teratogenic effects during pregnancy. The inclusion of bromocriptine in PPCM therapy seems to be justified, and in some cases improves the prognosis.

Abstract

Peripartum cardiomyopathy (PPCM) is defined as idiopathic cardiomyopathy which occurs at the end of pregnancy or in the first few months after delivery, with symptoms of heart failure (HF) secondary to left ventricular dysfunction, and at the same time no other cause for this condition. The pathomechanism of the disease has not yet been fully understood, but it is probably based on the interaction of complex factors. The clinical course of PPCM varies from life-threatening acute heart failure to mild symptoms mimicking the symptoms typical of the perinatal period. In Europe, PPCM is a rare disease but there are areas of the world where it occurs in one in every 300 cases. The treatment of PPCM is similar to that of HF with reduced ejection fraction. However, it is important to exclude drugs with teratogenic effects during pregnancy. The inclusion of bromocriptine in PPCM therapy seems to be justified, and in some cases improves the prognosis.
Get Citation

Keywords

peripartum cardiomyopathy; PPCM; heart failure; pregnancy; bromocriptine

About this article
Title

Peripartum cardiomyopathy: still unknown. The current state of knowledge

Journal

Folia Cardiologica

Issue

Vol 14, No 3 (2019)

Pages

315-323

Published online

2019-07-04

Bibliographic record

Folia Cardiologica 2019;14(3):315-323.

Keywords

peripartum cardiomyopathy
PPCM
heart failure
pregnancy
bromocriptine

Authors

Kiet Anh Nguyen
Kamila Gniady
Małgorzata Lelonek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl